These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 3287450)

  • 1. Immunomodulation of neoplasia by interleukin 2.
    Rossio JL; Ruscetti FW
    Prog Exp Tumor Res; 1988; 32():174-86. PubMed ID: 3287450
    [No Abstract]   [Full Text] [Related]  

  • 2. [Interleukin-2 and cancer immunotherapy].
    Ogarkov VI; Dobkin AI; Ryzhova EV; Okulov VB; Kiselev OI
    Vopr Onkol; 1989; 35(2):141-50. PubMed ID: 2648678
    [No Abstract]   [Full Text] [Related]  

  • 3. Natural killer cells and tumor immunity: 1985.
    Herberman RB
    Year Immunol; 1986; 2():254-60. PubMed ID: 3033946
    [No Abstract]   [Full Text] [Related]  

  • 4. [Use of interleukin 2-activated lymphocytes (LAK cells) in adoptive immunotherapy of neoplasms].
    Robak T
    Pol Tyg Lek; 1988 Nov; 43(47):1491-5. PubMed ID: 3266975
    [No Abstract]   [Full Text] [Related]  

  • 5. Human and mouse "LAK" cells expanded in long-term cultures: in vitro and in vivo studies.
    Kedar E; Zeira E; Lebendiker Z; Weiss DW; Katan R; Shouval D
    Prog Clin Biol Res; 1987; 244():59-75. PubMed ID: 3498959
    [No Abstract]   [Full Text] [Related]  

  • 6. Interleukin-2 activated cytotoxic lymphocytes and their application in the intraoperative immunotherapy of local tumors.
    Grimm EA
    Prog Clin Biol Res; 1987; 244():185-95. PubMed ID: 3498948
    [No Abstract]   [Full Text] [Related]  

  • 7. "Lymphokine activated killing" as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes.
    Sondel PM; Hank JA; Kohler PC; Chen BP; Sosman J
    Prog Clin Biol Res; 1989; 288():151-60. PubMed ID: 2654949
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune surveillance and neoplasia. I. A minimal mathematical model.
    DeLisi C; Rescigno A
    Bull Math Biol; 1977; 39(2):201-21. PubMed ID: 851661
    [No Abstract]   [Full Text] [Related]  

  • 9. Interleukin-2 and lymphokine-activated killer cell therapy for gastrointestinal cancer.
    Guillou P
    Acta Chir Scand Suppl; 1989; 549():26-30. PubMed ID: 2784604
    [No Abstract]   [Full Text] [Related]  

  • 10. The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
    Ettinghausen SE; Rosenberg SA
    Springer Semin Immunopathol; 1986; 9(1):51-71. PubMed ID: 3523804
    [No Abstract]   [Full Text] [Related]  

  • 11. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.
    Rosenberg SA; Lotze MT
    Annu Rev Immunol; 1986; 4():681-709. PubMed ID: 3518753
    [No Abstract]   [Full Text] [Related]  

  • 12. [Adoptive immunotherapy: a new therapeutic approach to cancer based on interleukin 2].
    Sculier JP; Bron D; Delforge A; Stryckmans P; Klastersky J
    Rev Med Brux; 1987 Mar; 8(3):133-9. PubMed ID: 3495843
    [No Abstract]   [Full Text] [Related]  

  • 13. An explanation of the variable clinical response to interleukin 2 and LAK cells.
    Parmiani G
    Immunol Today; 1990 Apr; 11(4):113-5. PubMed ID: 2187466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interleukin 2].
    Voĭtenok NN
    Ter Arkh; 1988; 60(5):42-6. PubMed ID: 3051488
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunobiology of human gliomas.
    Bullard DE; Gillespie GY; Mahaley MS; Bigner DD
    Semin Oncol; 1986 Mar; 13(1):94-109. PubMed ID: 2420011
    [No Abstract]   [Full Text] [Related]  

  • 16. Interleukins and the immune system 1.
    O'Garra A
    Lancet; 1989 Apr; 1(8644):943-7. PubMed ID: 2565429
    [No Abstract]   [Full Text] [Related]  

  • 17. [A new hypothesis on the immune surveillance of tumors].
    Jansa P
    Acta Univ Palacki Olomuc Fac Med; 1984; 107():139-42. PubMed ID: 6242634
    [No Abstract]   [Full Text] [Related]  

  • 18. Human interleukin 2: molecular biology, physiology and clinical possibilities.
    Mertelsmann R; Welte K
    Immunobiology; 1986 Sep; 172(3-5):400-19. PubMed ID: 3100434
    [No Abstract]   [Full Text] [Related]  

  • 19. [Immunotherapy with interleukin 2].
    Steinmetz T
    Krankenpfl J; 1991 Jun; 29(6):237-42. PubMed ID: 1861441
    [No Abstract]   [Full Text] [Related]  

  • 20. Letter: Immune surveillance revisited.
    Law LW
    J Natl Cancer Inst; 1975 Jan; 54(1):280-2. PubMed ID: 1113309
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.